# NGM Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ngm-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.ngmbio.com
- Total disclosed funding: $251M
- Latest round: Series A (Jul 17, 2024)
- Investors on record: 6

## About

Founded in 2008 and based in California, US, NGM Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. In July 2024, NGM Biopharmaceuticals, Inc. raised USD 122 million in series A funding led by investor The Column Group. The firm as of July 2024, is led by its CEO, David J. Woodhouse.

NGM's Discovery Engine drives the creation of biologic drug candidates. This engine integrates advanced protein and antibody engineering with deep biological expertise to identify and develop therapies for diseases like Primary Sclerosing Cholangitis, Hyperemesis Gravidarum, and various advanced solid tumors. The company's pipeline comprises Aldafermin for Primary Sclerosing Cholangitis, NGM120 for Hyperemesis Gravidarum, NGM707 + pembrolizumab for Advanced Solid Tumors, etc.

The company plans to utilize the July 2024 funding to support the clinical and registrational trial of its product called Aldafermin.

## Funding rounds

- Series A, Jul 17, 2024, $122M — The Column Group
- Series D, Oct 9, 2014, $21M — Prospect Venture Partners, The Column Group, Topspin Partners, Tichenor Ventures
- Series C, May 2, 2013, $13M — Prospect Venture Partners, RHO, The Column Group, Topspin Partners, Tichenor Ventures
- Series B, Nov 3, 2011, $17M — Prospect Venture Partners, RHO, The Column Group, Tichenor Ventures
- Series B, Mar 15, 2010, $51M — Prospect Venture Partners, RHO, The Column Group, Tichenor Ventures, Takeda Ventures
- Series A, Dec 18, 2009, $9.6M — Prospect Venture Partners, RHO, The Column Group
- Series A, Feb 24, 2009, $8.5M — Prospect Venture Partners, RHO
- Series A, Feb 1, 2008, $8.4M — Prospect Venture Partners, RHO, The Column Group

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series A, Series B, Series C, Series D
- RHO (https://capitalatlas.ai/funds/rho) — Series A, Series B, Series C
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C, Series D
- Tichenor Ventures — Series B, Series C, Series D
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series C, Series D